ELAN (Elanco Animal Health) EBIT: $40 Mil (TTM As of Mar. 2026)


ELAN Elanco Animal Health Inc ELAN
66 GF Score
Price $23.93
GF Value $15.57
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Elanco Animal Health EBIT?

Elanco Animal Health ELAN +3.24% 66 EBIT is $40 Mil as of Mar. 2026. GuruFocus rates ELAN with a GF Score™ of 66/100 and a GF Value™ of $15.57 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Elanco Animal Health's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $144 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $40 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Elanco Animal Health's annualized ROC % for the quarter that ended in Mar. 2026 was 3.56%. Elanco Animal Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 20.48%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Elanco Animal Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.26%.


Elanco Animal Health  (NYSE:ELAN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Elanco Animal Health's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=676 * ( 1 - 34.48% )/( (12445 + 12422)/ 2 )
=442.9152/12433.5
=3.56 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Elanco Animal Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=576/( ( (1409 + max(1323, 0)) + (1395 + max(1497, 0)) )/ 2 )
=576/( ( 2732 + 2892 )/ 2 )
=576/2812
=20.48 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(873 + 1737 + 236) - (368 + 416 + 739)
=1323

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1084 + 1717 + 285) - (372 + 400 + 817)
=1497

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Elanco Animal Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=40/15514.827
=0.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elanco Animal Health EBIT Related Terms


Elanco Animal Health EBIT Historical Data

* Premium members only.

The historical data trend for Elanco Animal Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elanco Animal Health EBIT Chart

Elanco Animal Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -335.00 169.00 -918.00 723.00 -4.00

Elanco Animal Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 73.00 2.00 -179.00 144.00

ELAN vs RGC, NBIX, ALKS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elanco Animal Health EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Elanco Animal Health's EV-to-EBIT falls into.


ELAN
66GF Score
Elanco Animal Health Inc ELAN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elanco Animal Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $40 Mil mean?
Elanco Animal Health (ELAN) has a EBIT of $40 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Elanco Animal Health.
Is Elanco Animal Health's EBIT too high?
Elanco Animal Health's current EBIT is $40 Mil. Overall, Elanco Animal Health has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's EBIT compare to RGC and NBIX?
Elanco Animal Health's EBIT of $40 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Elanco Animal Health. Elanco Animal Health's current EBIT is $40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Elanco Animal Health (ELAN) is currently considered Significantly Overvalued. The stock's GF Value™ is $15.57, compared to a current price of $23.93 — trading 53.7% above its estimated fair value. The current EBIT is $40 Mil. Elanco Animal Health's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Elanco Animal Health (ELAN), the current EBIT is $40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elanco Animal Health (ELAN) Overvalued in 2026?

Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued. The current stock price of $23.93 is trading 53.7% above its estimated GF Value™ of $15.57. GuruFocus considers Elanco Animal Health to be Significantly Overvalued.

Key valuation signals for ELAN:

  • EBIT: $40 Mil
  • GF Value™: $15.57 vs. price of $23.93 (53.7% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the ELAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Elanco Animal Health Business Description

Other Exchanges 5EA:Germany
Address 450 ELANCO CIRCLE, INDIANAPOLIS, IN, USA, 46221
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
66GF Score

Get the complete analysis for ELAN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.93
Price
$15.57
GF Value